Sight Sciences
SGHT
About: Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Employees: 216
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
113% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 16
76% more capital invested
Capital invested by funds: $55.3M [Q1] → $97.1M (+$41.8M) [Q2]
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
3% more funds holding
Funds holding: 77 [Q1] → 79 (+2) [Q2]
0.39% more ownership
Funds ownership: 40.41% [Q1] → 40.8% (+0.39%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $57K
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
Citigroup
Joanne Wuensch
|
$4.5
|
Neutral
Maintained
|
21 Aug 2025 |
|
Lake Street
Frank Takkinen
|
$5
|
Buy
Upgraded
|
8 Aug 2025 |
|
Morgan Stanley
Cecilia Furlong
|
$4
|
Equal-Weight
Maintained
|
15 Jul 2025 |
|
Piper Sandler
Adam Maeder
|
$4
|
Neutral
Maintained
|
18 Jun 2025 |
Financial journalist opinion
Based on 4 articles about SGHT published over the past 30 days
